U.S. market Open. Closes in 6 hours 5 minutes

JANX | Janux Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue8.08M8.61M3.64MN/AN/A
Cost of Revenue1.96M841.00K113.00K13.00K6.00K
Gross Profit6.13M7.77M3.52M-13.00K-6.00K
Operating Expenses81.06M75.70M36.57M4.84M3.77M
Selling, General & Admin26.14M22.26M10.33M1.80M772.00K
Research & Development54.92M53.44M26.24M3.04M3.00M
Other Operating Expenses-54.92M4.03M257.00K-1.74MN/A
Operating Income-72.98M-67.09M-32.93M-4.84M-3.77M
Other Expenses / Income14.69M4.03M257.00K-1.94M-233.00K
Before Tax Income-58.29M-63.06M-32.67M-6.78M-4.00M
Income Tax Expenses1.79M-8.90M-113.00K-1.53M233.00K
Net Income-58.29M-54.15M-32.56M-5.25M-4.24M
Interest ExpensesN/A4.03MN/A206.00K233.00K
Basic Shares Outstanding44.02M41.47M41.24M41.61M41.61M
Diluted Shares Outstanding44.02M41.47M41.24M41.61M41.61M
EBITDA-71.02M-67.09M-32.93M-6.57M-3.77M
EBITDA Margin-878.68%-779.04%-905.39%0.00%0.00%
EBIT-56.51M-59.03M-32.67M-6.58M-3.77M
EBIT Margin-699.07%-685.40%-898.32%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙